Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate, Incorrect route of product administration, Injection site erythema, Injection site reaction, Injection site warmth
Clinical narrative: Inflammation and a gritty feeling in my other (left) eye; Paranoid second dose was not authentic; vertigo; delayed reaction five days later at the injection site.; red and hot to touch; red and hot to touch; Dry skin; second dose was administered subcutaneously; Arm was quite swollen; A little red; This spontaneous case was reported by a consumer and describes the occurrence of EYE INFLAMMATION (Inflammation and a gritty feeling in my other (left) eye), PARANOIA (Paranoid second dose was not authentic), PERIPHERAL SWELLING (Arm was quite swollen), ERYTHEMA (A little red) and VERTIGO (vertigo) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension and Eye inflammation (She also is having some inflammation and a gritty feeling in her left eye. She experienced a similar situation for many years in the 1960s.). Concomitant products included NEBIVOLOL HYDROCHLORIDE (BYSTOLIC) and AMLODIPINE BESILATE (NORVASC) for Hypertension.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Feb-2021, the patient experienced PERIPHERAL SWELLING (Arm was quite swollen) and ERYTHEMA (A little red). On an unknown date, the patient experienced EYE INFLAMMATION (Inflammation and a gritty feeling in my other (left) eye), PARANOIA (Paranoid second dose was not authentic), VERTIGO (vertigo), INJECTION SITE REACTION (delayed reaction five days later at the injection site.), INJECTION SITE WARMTH (red and hot to touch), INJECTION SITE ERYTHEMA (red and hot to touch), DRY SKIN (Dry skin) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (second dose was administered subcutaneously). At the time of the report, EYE INFLAMMATION (Inflammation and a gritty feeling in my other (left) eye), PARANOIA (Paranoid second dose was not authentic), VERTIGO (vertigo), INJECTION SITE REACTION (delayed reaction five days later at the injection site.), INJECTION SITE WARMTH (red and hot to touch), INJECTION SITE ERYTHEMA (red and hot to touch), DRY SKIN (Dry skin) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (second dose was administered subcutaneously) outcome was unknown and PERIPHERAL SWELLING (Arm was quite swollen) and ERYTHEMA (A little red) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Feb-2021, Blood pressure measurement: 169/96 (High) Blood pressure at 169/96 which was high for her. It is usually somewhere around 140/80 and has returned to that.. On an unknown date, Antibody test: positive (Positive) Tested for antibodies and has had a positive antibody test prior to receiving both doses of the vaccine. and negative (Negative) After taking both the doses of Moderna vaccine she tested negative for antibodies.. On an unknown date, Heart rate: 30 (Low) Her heartrate dropped down into the 30's. Sometimes her heartrates drops down into the 50's but never the 30's..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication included Steroid  Eye Drops, 1-3 times a day. Patient also reports using "cream" for event dry skin. Patient reports that she took  extra 2.5 mg of Norvasc  since her blood pressure was higher than normal. On 23 Apr 2021 the patient reports that when the second dose was administered the nurse squeezed patient's arm and it felt like a scratch.  On 02 Jun 2021, the patient reports that she recently went to have a colonoscopy done and it was incomplete because her heartrate dropped.   This case was linked to MOD-2021-031273 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Significant follow-up On 24-Jun-2021: Initial Additional- 4